Retroperitoneal Alveolar Soft Part Sarcoma Mimicking Paraganglioma: A Case Report
DOI:
https://doi.org/10.21276/apalm.3845Keywords:
alveolar soft part sarcoma, TFE3 protein, retroperitoneal neoplasms, paraganglioma, immunohistochemistry, diagnostic imagingAbstract
Alveolar soft part sarcoma (ASPS) is an uncommon soft tissue malignancy that rarely arises in the retroperitoneum. Its marked hypervascularity on imaging creates diagnostic confusion with paraganglioma, potentially leading to misdiagnosis. We present a case of a 33-year-old male patient with a seven-month history of a progressively enlarging left iliac fossa mass. Cross-sectional imaging demonstrated a 17×10×8 cm hypervascular retroperitoneal mass arising from the left iliopsoas region and displacing adjacent structures, with intense arterial enhancement, suggesting paraganglioma. Plasma metanephrines were normal. Surgical debulking was performed. Histopathology revealed characteristic organoid-alveolar architecture with nests separated by fibrovascular septa and pseudoalveolar spaces. Tumour cells exhibited abundant eosinophilic granular cytoplasm with PAS-D positive intracytoplasmic crystals. Immunohistochemistry showed strong nuclear TFE3 positivity whilst neuroendocrine, epithelial, renal, myogenic, and melanocytic markers were negative, confirming ASPS. This case highlights that retroperitoneal ASPS can convincingly mimic paraganglioma radiologically. Recognition of characteristic histomorphology and TFE3 immunoexpression is essential for accurate diagnosis. Surgical management and long-term surveillance are crucial given the propensity for late metastases.References
1. Christopherson WM, Foote FW, Stewart FW. Alveolar soft-part sarcomas: structurally characteristic tumors of uncertain histogenesis. Cancer. 1952;5(1):100-111.
2. WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. 5th ed. Lyon: International Agency for Research on Cancer; 2020.
3. Fujiwara T, Kunisada T, Nakata E, Nishida K, Yanai H, Nakamura T, et al. Advances in treatment of alveolar soft part sarcoma: an updated review. Jpn J Clin Oncol. 2023;53(11):1009-1018.
4. Ladanyi M, Lui MY, Antonescu CR, Krause-Boehm A, Meindl A, Argani P, et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene. 2001;20(1):48-57.
5. Zhang Y, Huang Y, Qin Y, Yang N, Yang P, Li N, et al. Alveolar soft part sarcoma: a clinicopathological and immunohistochemical analysis of 26 cases emphasizing risk factors and prognosis. Diagn Pathol. 2024;19(1):23.
6. Wang H, Jacobson M, Neville A, Campbell MJ, Tran T. Clinicopathological and radiological analysis of alveolar soft part sarcoma: a single institution study. Pathol Res Pract. 2013;209(7):449-456.
7. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, et al. Pheochromocytoma and paraganglioma: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942.
8. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27(6):750-761.
9. Stacchiotti S, Tamborini E, Marrari A, Brich S, Rota SA, Orsenigo M, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res. 2009;15(3):1096-1104.
10. Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial. Lancet Oncol. 2021;22(6):837-848.
11. Chen AP, Sharon E, O'Sullivan-Coyne G, Moore N, Foster JC, Hu JS, et al. Atezolizumab for advanced alveolar soft part sarcoma. N Engl J Med. 2023;389(10):911-921.
12. Argani P, Aulmann S, Illei PB, Netto GJ, Ro J, Cho HY, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010;34(10):1395-1406.
13. Kaur K, Gami A, Shah A, Gandhi J, Trivedi P. Clinico-pathological spectrum of alveolar soft part sarcoma: case series from a tertiary care cancer referral centre in India with a focus on unusual clinical and histological features. Turk Patoloji Derg. 2024;40(2):89-100.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Vishal Tayade, Rachana Binayke, Atul Gawad, Anand Ghuge, Pooja Ande, Sushma Ramraje
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).
How to Cite
